Skip to main content

TaoWeave, Inc.

For the period ended Dec 31, 2025. Filed Mar 20, 2026.

View on SEC.gov

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2025 · Filed Mar 20, 2026

TWAV$1.20-5.5%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits
Contents

Item 14. Principal Accounting Fees and Services

The audit committee, composed entirely of independent, non-employee members of the Board of Directors, appointed the firm of EisnerAmper LLP, Iselin, New Jersey (“EisnerAmper”), PCAOB identification number 274, as the independent registered public accounting firm for the audit of the Consolidated Financial Statements of the Company and its subsidiaries for the fiscal years ending December 31, 2025, and 2024. As our independent registered public accounting firm, EisnerAmper audited our Consolidated Financial Statements for the fiscal year ending December 31, 2025, reviewed the related interim quarters, and performed audit-related services and consultation on various accounting and financial reporting matters. EisnerAmper may also perform certain non-audit services for our Company. The audit committee has determined that the provision of the services provided by EisnerAmper as set forth herein are compatible with maintaining EisnerAmper’s independence and the prohibitions on performing non-audit services set forth in the Sarbanes-Oxley Act and relevant SEC rules.

Audit Fees

EisnerAmper, our principal accountant, billed the Company approximately $239,000 for professional services related to the audit of our annual Consolidated Financial Statements for the 2025 fiscal year and the reviews of the Consolidated Financial Statements included in our quarterly reports on Form 10-Q for the 2025 fiscal year. EisnerAmper billed us $251,000 for professional services for the audit of our annual Consolidated Financial Statements for the 2024 fiscal year, and the reviews of the Consolidated Financial Statements included in our quarterly reports on Form 10-Q for the 2024 fiscal year.

Audit-Related Fees

EisnerAmper did not bill the Company for any audit-related fees in the 2025 and 2024 fiscal years.

Tax Fees

EisnerAmper did not bill the Company for any professional services rendered for tax compliance, tax advice, or tax planning in the 2025 and 2024 fiscal years.

All Other Fees

EisnerAmper did not bill the Company for any products and services other than the audit described above during the 2025 and 2024 fiscal years.

Audit Committee Pre-Approval Policy

The audit committee is required to pre-approve the EisnerAmper engagement to perform audit and other services for the Company. Our procedures for the audit committee's pre-approval of all services provided by EisnerAmper comply with SEC regulations regarding pre-approval of services. Services subject to these SEC requirements include audit services, audit-related services, tax services, and other services. The audit engagement is specifically approved, and the auditors are retained by the audit committee. The audit committee has also adopted policies and procedures for pre-approving all non-audit work performed by EisnerAmper. In accordance with audit committee policy and the requirements of law, all services provided by EisnerAmper in the 2025 and 2024 fiscal years were pre-approved by the audit committee, and all services to be provided by EisnerAmper will be pre-approved. Pre-approval includes audit services, audit-related services, tax services, and other services. To avoid certain potential conflicts of interest, the law prohibits a publicly traded company from obtaining certain non-audit services from its auditing firm. We obtain these services from other service providers as needed.

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.